1. Home
  2. GSIW vs SCYX Comparison

GSIW vs SCYX Comparison

Compare GSIW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

HOLD

Current Price

$0.13

Market Cap

28.6M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.60

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
SCYX
Founded
2016
1999
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6M
26.3M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
GSIW
SCYX
Price
$0.13
$0.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
299.7K
366.6K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,368,221.00
$2,932,000.00
Revenue This Year
N/A
$167.73
Revenue Next Year
N/A
$290.78
P/E Ratio
N/A
N/A
Revenue Growth
283.23
N/A
52 Week Low
$0.09
$0.57
52 Week High
$1.79
$1.49

Technical Indicators

Market Signals
Indicator
GSIW
SCYX
Relative Strength Index (RSI) 39.19 33.43
Support Level $0.13 $0.58
Resistance Level $0.14 $0.63
Average True Range (ATR) 0.01 0.02
MACD -0.00 -0.00
Stochastic Oscillator 12.65 18.76

Price Performance

Historical Comparison
GSIW
SCYX

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: